[{"id":"35e608cc-539c-4ac1-a89a-c289c5e8a0c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01522404","created_at":"2021-01-18T06:24:18.792Z","updated_at":"2024-07-02T16:36:57.820Z","phase":"Phase 2","brief_title":"Effects of Atomoxetine in Mild Cognitive Impairment","source_id_and_acronym":"NCT01522404","lead_sponsor":"Emory University","biomarkers":" IL1A • APOE • CYP2D6","pipe":"","alterations":" ","tags":["IL1A • APOE • CYP2D6"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 10/31/2017","primary_completion_date":" 10/31/2017","study_txt":" Completion: 06/30/2018","study_completion_date":" 06/30/2018","last_update_posted":"2019-07-23"},{"id":"b483241f-0ff3-439b-ab24-ad35c3d78ac0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03137368","created_at":"2021-01-18T15:27:49.316Z","updated_at":"2024-07-02T16:37:05.684Z","phase":"Phase 3","brief_title":"A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）","source_id_and_acronym":"NCT03137368","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2 • ER • PGR • CYP2D6","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR • CYP2D6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • exemestane • goserelin acetate"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 300","initiation":"Initiation: 08/09/2018","start_date":" 08/09/2018","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2018-10-31"}]